candesartan has been researched along with Brain Injuries in 5 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Brain Injuries: Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan treatment reduced the lesion volume after CCI injury by approximately 50%, decreased the number of dying neurons, lessened the number of activated microglial cells, protected cerebral blood flow (CBF), and reduced the expression of the cytokine TGFβ1 while increasing expression of TGFβ3." | 1.38 | Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. ( Logan, TT; Saavedra, JM; Sánchez-Lemus, E; Symes, AJ; Villapol, S; Yaszemski, AK, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Timaru-Kast, R | 1 |
| Coronel-Castello, SP | 1 |
| Krämer, TJ | 1 |
| Hugonnet, AV | 1 |
| Schäfer, MKE | 1 |
| Sebastiani, A | 1 |
| Thal, SC | 1 |
| Panahpour, H | 1 |
| Nekooeian, AA | 1 |
| Dehghani, GA | 1 |
| Villapol, S | 2 |
| Balarezo, MG | 1 |
| Affram, K | 1 |
| Saavedra, JM | 2 |
| Symes, AJ | 2 |
| Yaszemski, AK | 1 |
| Logan, TT | 1 |
| Sánchez-Lemus, E | 1 |
| Ozacmak, VH | 1 |
| Sayan, H | 1 |
| Cetin, A | 1 |
| Akyildiz-Igdem, A | 1 |
5 other studies available for candesartan and Brain Injuries
| Article | Year |
|---|---|
AT 1 inhibition mediated neuroprotection after experimental traumatic brain injury is dependent on neutrophils in male mice.
Topics: Animals; Brain; Brain Injuries; Brain Injuries, Traumatic; Homeodomain Proteins; Inflammation; Male; | 2023 |
Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Ba | 2014 |
Neurorestoration after traumatic brain injury through angiotensin II receptor blockage.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzamides; Benzimidazoles; Benzoates; | 2015 |
Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Injuries | 2012 |
AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2007 |